Clinical trial
Erlotinib in Treating Patients With Advanced Kidney Cancer
NCT00045487 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00045487 |
|---|---|
| Title | Erlotinib in Treating Patients With Advanced Kidney Cancer |
| Official title | A Phase II, Pharmacokinetic And Biologic Correlative Study of OSI-774, An EGFR Tyrosine Kinase Inhibitor, In Patients With Advanced Renal Cell Carcinoma |
| Acronym | OSI-774 |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | OSI-774 |
| Enrollment | 41 |
| Start date | Jun 1, 2002 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 27, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: